361-63-7

Usage

Uses

Used in Pharmaceutical Industry:
Bis(4-fluorophenyl)acetic acid is used as a building block for the synthesis of various pharmaceuticals and agrochemicals. Its role in the development of new drugs is attributed to its potential anti-inflammatory and analgesic properties, as well as its ability to inhibit the cyclooxygenase enzyme, which is crucial in the inflammatory response.
Used in Research and Development:
In the field of research and development, Bis(4-fluorophenyl)acetic acid is employed for the exploration of its therapeutic potential. It is studied for its potential to alleviate inflammation and pain, making it a valuable compound in the quest for new treatments for various conditions.
Used in Drug Synthesis:
As a key component in drug synthesis, Bis(4-fluorophenyl)acetic acid is used to create a variety of medications that target inflammation and pain. Its chemical properties make it a versatile building block for the development of effective pharmaceuticals.
Used in Inhibiting Inflammatory Response:
Bis(4-fluorophenyl)acetic acid is used as an inhibitor of the cyclooxygenase enzyme, which is a critical component in the inflammatory response. By inhibiting this enzyme, the compound can potentially reduce inflammation and associated pain, making it a valuable asset in the treatment of inflammatory conditions.

InChI:InChI=1/C14H10F2O2/c15-11-5-1-9(2-6-11)13(14(17)18)10-3-7-12(16)8-4-10/h1-8,13H,(H,17,18)

Upstream product

• 475-26-3 1,1'-(2,2,2-trichloroethylidene)bis(p-fluorobenzene) 
• 789-03-7 1,1,1-trifluoro-2,2-bis(p-fluorophenyl)ethane 
• 64-18-6 formic acid 
• 365-24-2 4,4'-difluorobenzhydryl alcohol 
• 733-83-5 2,2,2-trifluoro-1,1-bis(4-fluorophenyl)ethanol 
• 462-06-6 fluorobenzene 
• 298-12-4 Glyoxilic acid 
• 352-34-1 4-fluoro-1-iodobenzene 

Downstream Products

• 114785-22-7 (S)-5-[bis(4-fluorophenyl)acetyl]-4,5,6,7-tetrahydro-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridine-6-carboxylic acid 
• 386-99-2 ethyl 2,2-bis(4-fluorophenyl)acetate 
• 337-54-2 2,2-bis(4-fluorophenyl)propanoic acid 
• 1397711-73-7 2,2-bis(4-fluorophenyl)pent-4-enoic acid 
• 1397711-96-4 (S)-N-((4,4-bis(4-fluorophenyl)-5-oxocyclopent-1-enyl)(4-chlorophenyl)methyl)-4-methylbenzenesulfonamide 
• 1397711-95-3 (S)-N-((4,4-bis(4-fluorophenyl)-5-oxocyclopent-1-enyl)(p-tolyl)methyl)-4-methylbenzenesulfonamide 
• 1397711-94-2 (S)-N-((4,4-bis(4-fluorophenyl)-5-oxocyclopent-1-enyl)(4-nitrophenyl)methyl)-4-methylbenzenesulfonamide 
• 1397711-71-5 5,5-bis(4-fluorophenyl)cyclopent-2-enone 
• 2594-12-9 2,2-bis(4-fluorophenyl)-N-hydroxyacetamide 

Relevant academic research and scientific papers

Taming of superacids: PVP-triflic acid as an effective solid triflic acid equivalent for Friedel-Crafts hydroxyalkylation and acylation

The application of poly(4-vinylpyridine) supported trifluoromethanesulfonic acid (PVP-TfOH, 1:10) as a convenient solid superacid catalyst system in Friedel-Crafts reactions is described. In the presence of PVP-TfOH, one pot solvent-free synthesis of a wide variety of diarylacetic acid derivatives was achieved by Friedel-Crafts hydroxyalkylation reaction of glyoxylic acid with arenes under mild conditions. Acylation of both activated and deactivated aromatic compounds with acetyl chloride was also achieved using PVP-TfOH complex under solvent-free conditions at room temperature. As the polymer supported triflic acid was found to be a very efficient and an easy-to-handle solid acid, it can be a useful addition to environmentally more adaptable strong acid catalyst systems.

New multifunctional chiral phosphines and BINOL derivatives co-catalyzed enantioselective aza-Morita-Baylis-Hillman reaction of 5,5-disubstituted cyclopent-2-enone and N-sulfonated imines

New multifunctional chiral phosphine (phosphine-amide type) LB8 and BINOL derivative co-catalyzed asymmetric aza-MBH reaction of 5,5-disubstituted cyclopent-2-enones 1 with N-sulfonated imines 2 afforded the corresponding optically active adducts 3 in goo

Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors

We have identified a series of diphenylmethylene hydroxamic acids as novel and selective HDAC class IIa inhibitors. The original hit, N-hydroxy-2,2-diphenylacetamide (6), has sub-micromolar class IIa HDAC inhibitory activity, while the rigidified oxygen a

CYCLIC AMINE COMPOUND

An object of the present invention is to provide a cyclic amine compound which has a potent inhibitory effect on the binding of a2C-adrenoceptor and is useful in preventing and treating disorders attributable to a2C-adrenoceptor.The above-described object is solved by the following cyclic amine compound, etc., wherein X is O, S, SO, SO2 or NR2, etc.; R1 is a hydrogen atom, a cyano group, a carboxyl group, a C2-C13 alkoxycarbonyl group, a carbamoyl group, etc.; Ar1 and Ar2 are the same or different and each represent an aryl or heteroaryl group which may be substituted by 1 to 3 substituents and so on; ring B is a benzene ring may be substituted by 1 to 3 substituents and so on; n is an integer from 1 to 10; and p and q are the same or different and each represent an integer of 1 or 2.

Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 1. The discovery of arylacetamides as viable replacements for the dihydropyrimidinone moiety of an HTS hit

Melanin-concentrating hormone (MCH) is involved in the regulation of feeding, water balance, energy metabolism, general arousal and attention state, memory, cognitive functions, and psychiatric disorders. Herein, two new chemical series exemplified by N-[5-(1-{3-[2,2-bis-(4-fluoro-phenyl)-acetylamino]- propyl}-piperidin-4-yl)-2,4-difluoro-phenyl]-isobutyramide (SNAP 102739, 5m) and N-[3-(1-{3-[(S)-2-(4-fluorophenyl)-propionylamino]-propyl}-piperidin-4-yl)-4- methylphenyl]-isobutyramide ((S)-6b) are reported. These compounds were designed to improve the pharmacokinetic properties of the high-throughput screening lead compound 1 (SNAP 7941). The MCH1 receptor antagonists 5m and (S)-6b show reasonable pharmacokinetic profiles (rat bioavailability = 48 and 81%, respectively). Compounds 5m and (S)-6b demonstrated the inhibition of a centrally administered MCH-evoked drinking effect, and compound 5m exhibited oral in vivo efficacy in the rat social interaction model of anxiety, with a minimum effective dose = 0.3 mg/kg.

MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS CONTAINING PIPERIDINE DERIVATIVES AS THE ACTIVE INGREDIENT

The invention provides melanin-concentrating hormone receptor antagonists containing as the active ingredient piperidine derivatives represented by the general formula [I]: ???[wherein R1 is hydrogen, hydroxyl, lower alkyl, or the like; R2, R3a, R3b, R4a, R4b, R5a, R5b and R6 each stands for hydrogen, halogen, or the like; W1 and W2 each independently stands for -O-, -CH2-, or the like; Y1, Y2, Y3 and Y4 stand for -CH-, -CF-, -N-, or the like; Z stands for lower alkyl, an aliphatic heterocyclic group, or the like; Ar is a mono- or bi-cyclic aliphatic heterocycle or an aromatic heterocycle; and n is an integer of 1 to 8]. The compounds act as antagonist against melanin-concentrating hormone receptor and are useful as drugs for central diseases, circulatory diseases, or metabolic diseases.

Anticonvulsant and central nervous system-depressing bis(fluorophenyl)alkylamides and their uses

Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological diseases or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacological half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

A Study of the Ferrous Ion-initiated SRN1 Reactions of Halogenoarenes with tert-Butyl Acetate and N-Acylmorpholine Enolates

A detailed preparative study is reported of the ferrous ion-initiated SRN1 reactions of a range of halogenoarenes with the sodium enolates of tert-butyl acetate, n-acetylmorpholine and a number of higher N-acylmorpholines.Smooth and rapid substitution occurs in many cases, and good to excellent yields were obtained of arylacetic esters or acids, arylacetamides and arylalkanamides.The broad scope and limitations of the process have been defined, and the possible role of the ferrous ion is discussed.

CARBOXYLATION OF ALCOHOLS WITH CARBON MONOXIDE SUPERSATURATED IN STRONG ACID. FACILE SYNTHESIS OF 2,2-BIS(4-HALOPHENYL)ACETIC, -PROPIONIC, AND RELATED ACIDS

Using 97percent H2SO4 supersaturated with carbon monoxide, bis(4-halophenyl)methanols, 1,1-bis(4-halophenyl)ethanols and related alcohols were transformed to the carboxylic acids in 60-95percent yields.